.
"If you are a MSer at the Royal London Hospital please sign-up for our cognition study!"
We may be slow at answering this Month
35 comments:
- AnonymousFriday, August 17, 2012 4:20:00 PMI think the new posting format is better because I couldn't read the code numbers sometimes, now it's quicker.ReplyDelete
If people want to spam, they will regardless let's hope they discover some other blog to do so.
Also, could someone please tell the other researchers from Team G to increase the typing size of their articles? Thanks.
- AnonymousSaturday, August 18, 2012 1:12:00 PMOh MouseDoc:-) No code numbers just the stuff you had to type (letters+numbers) so that your post got through - now, how do you name that?ReplyDelete
Anyway, thanks for increasing the font, very helpful!! - AnonymousTuesday, August 21, 2012 3:43:00 PMAnother not Campath-related:-) question but perhaps some of the docs has time to answer - can you tell how much a blood test for Aquaporin-4 would cost me if I were to cover for it privately - just roughly need to know if I need to sell my car or something ;-) thanks.ReplyDelete
- This article will cheer up Prof GReplyDelete
Not sure why it would cheer us up, we have no real axe to grind with the Zamboni hypothesis except that we want definative proof the CCSVI hypothesis has legs, which is increasingly unlikely. We are saddened by the false hope and resource and human costs that this so called "eccentric and maverick" (by an A from Cambridge) idea has appeared to consume.
That MS suceptibility genes are largely immune related is not new we have known about this for years...therefore it is not news. The generation of this information has likewise not smelt of roses along its history.
However if I said I dont think that progressive MS is not anything to do with autoimmunity this could be true and this could still require immune related genes in its trigger. The question is can the vascular protagonists build the fact into their ideas, with something that is not a shaggy dog hypothesis. This has always been a problem with the CCSVI story that it brushes many on the known facts about MS aside. - AnonymousTuesday, August 28, 2012 2:10:00 PMFrom Prof G's twitter feed on 15 November 2010ReplyDelete
-a successful MS prevention strategy will destroy the MS DMT market! Whoopee bring it on
-A small molecule DMTs coming off patent may do it sooner or maybe not as they are not that effective. A cure is what we want!
Could BG12 be the small molecule DMT that eventually destroys the MS market? - AnonymousTuesday, August 28, 2012 6:31:00 PMBG12 destroying the market? Why not, you can buy fumaric acid over the counter. It could become a health or food supplement.ReplyDelete
- Could BG12 be the small molecule DMT that eventually destroys the MS market?ReplyDelete
Unlikely...try iv cladribine..any white knights out there?
- Interesting that Oracle was CIS. If the results are promising, that's taking early, aggressive to a new level (i.e. induction treatment at CIS stage). Is off label IV clad a reasonable strategy for new CISers to consider with their neuros? If it can be shown to significantly reduce risk of conversion to MS then it could be extremely important.ReplyDelete
Who is responsible for Oracle? Presumably not Merck given they've abandoned oral Clad? - Oral Cladribine in Early Multiple Sclerosis (MS) (ORACLE MS)NCT00725985 is Merck Serono trial July 2011 (Final data collection date for primary outcome measure Jul 2011) n = 617. Endpoint time to MS conversionReplyDelete
Oral Cladribine binned by EMS23 June 2011.....What's the interest from EMS in putting resource into study to tell us the result?
If Movecto was on the agenda still I suspect it would have been all over ECTRIMS this year if it had worked......now I bet it will make as much of a splash as pin dropping in to a big lake.
IV clad needs safety study to be done, remember it did not get FDA/European approval because of potential cancer signature. - AnonymousThursday, August 30, 2012 5:14:00 PMDo you expect we'll get the results at ECTRIMS? Are we certain this data is being collated? I can't see why EMS would do this given Oral Clad has been binned? Safety aside, it will be interesting to see the results. I'm certainly considering IV Clad off-label - cancer risk or not - now Alem is off the agenda for the time being.ReplyDelete
- Do you expect we'll get the results at ECTRIMS? ...No.....Not this year. If you look at the ECTRIMS website you can see titles of most of the presentationsReplyDelete
Are we certain this data is being collated?....No...But I don't know..should be
I can't see why EMS would do this given Oral Clad has been binned? ...It will not be high on the agenda I'm sure but will come out at some stage..Prof G thought next year
- AnonymousThursday, August 30, 2012 8:08:00 PMThanks. On a different topic - what's the most anticipated 'release' at ECTRIMS? Are there any really exciting trial result or developments expected to be revealed for the first time??ReplyDelete
- I think there will be the Pharam Jamboree, but you know most of what they are serving upReplyDelete
Here is the preliminary programme
http://www.congrex.ch/fileadmin/files/2012/ectrims2012/ebooks/ECTRIMS_2012_Preliminary_Programme/index.html
Prof G will no doubt we sending updates from Lyon
- Dear Anon 11.15ReplyDelete
Saw Prof G at lunch time and mentioned your comment, it reminded him to think about food in France as he thinks Lyon will have some nice places to eat..after all it will be french food.
- AnonymousFriday, August 31, 2012 5:25:00 PMGood luck & a big thank you to Maria & Beki!ReplyDelete
Both of them will be missed
http://www.nelm.nhs.uk/en/NeLM-Area/News/2012---August/10/Discontinuation-of-licensed-supplies-of-alemtuzumab-Mabcampath/
I guess it will return at a much higher price when it is licensed for MS